$ORGS News

Last published 1y ago

1y agoORGSOrgenesis Provides Third Quarter 2024 Business UpdateGlobeNewswireGERMANTOWN, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (OTCQX: ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to
2y agoORGSOrgenesis Commences Trading on OTCQX® Best MarketGlobeNewswireReports Plans to Reapply for Nasdaq Listing Announces Progress Advancing Decentralized Cell Processing Platform GERMANTOWN, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the
2y agoORGSOrgenesis Announces Reverse Stock SplitGlobeNewswireGERMANTOWN, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company") today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's
2y agoORGSOrgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic LeukemiaGlobeNewswireOrgenesis' CD19 CAR-T therapy, ORG-101, had a complete response (CR) of 82% in adults and 93% in pediatric patients with the incidence of severe Cytokine Release Syndrome (CRS) of 2% in adult patients and 6% in pediatric
2y agoORGSOrgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative GloballyGlobeNewswireGERMANTOWN, Md., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to
2y agoORGSOrgenesis Provides Second Quarter 2024 Business UpdateGlobeNewswireGERMANTOWN, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to
2y agoORGSOrgenesis Provides Business Update for the First Quarter of 2024GlobeNewswireGERMANTOWN, Md., May 21, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to
2y agoORGSOrgenesis Provides Year End Business UpdateGlobeNewswireMajor transformation underway commencing with recent acquisitionreasserting full ownership and control over Octomera Secured a $2.3 million investment from a group including sophisticated healthcare professionals at
2y agoORGSGermfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global AccessibilityGlobeNewswireORMOND BEACH, Fla. and GERMANTOWN, Md., April 10, 2024 (GLOBE NEWSWIRE) -- Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (NASDAQ:ORGS), a global leader in
2y agoORGSVered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe ConferenceGlobeNewswireGERMANTOWN, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global leader in decentralizing cell and gene therapies (CGTs), today announced that its CEO, Vered
2y agoORGSOrgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic ExosomesGlobeNewswireGERMANTOWN, Md., March 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global leader in decentralizing cell and gene therapies (CGTs), today announced that the Company has
2y agoORGSOrgenesis Inc. Announces $2.3 Million Private PlacementGlobeNewswireGERMANTOWN, Md., March 04, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global leader in decentralized cell and gene therapies (CGTs), announced today that it has entered into
2y agoORGSOrgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP ManufacturingGlobeNewswireGERMANTOWN, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global leader in decentralized cell and gene therapies (CGTs), today announced that the Company's
2y agoORGSOrgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to ClinicGlobeNewswireGERMANTOWN, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global leader in decentralizing cell and gene therapies (CGTs), today announced it has entered into a
2y agoORGSOrgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TMGlobeNewswireGERMANTOWN, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today
2y agoORGSOrgenesis Provides Business Update for the Third Quarter of 2023GlobeNewswireGERMANTOWN, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today
3y agoORGSOrgenesis Inc. Announces Pricing of $1.1 Million Registered Direct OfferingGlobeNewswireGERMANTOWN, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. ("Orgenesis") (NASDAQ:ORGS), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), announced today that it
3y agoORGSOrgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant FundingGlobeNewswireGERMANTOWN, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), today
3y agoORGSOrgenesis Announces Withdrawal of Proposed Public OfferingGlobeNewswireGERMANTOWN, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today
3y agoORGSOrgenesis Announces Proposed Underwritten Public OfferingGlobeNewswireGERMANTOWN, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today
3y agoORGSCGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United StatesGlobeNewswireGERMANTOWN, Maryland, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs),
3y agoORGSCell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service SupportGlobeNewswireGERMANTOWN, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orgenesis, a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), continues to grow the infrastructure of the advanced
3y agoORGSOrgenesis Provides Business Update for Second Quarter of 2023GlobeNewswireReports Progress in Advancing the Rollout of the POCare Platform and POCare Therapeutic Pipeline Orgenesis to Host Conference Call Today at 8:00 AM ET GERMANTOWN, Md., Aug. 11, 2023 (GLOBE
3y agoORGSOrgenesis Schedules Second Quarter 2023 Business Update Conference CallGlobeNewswireGERMANTOWN, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today
3y agoORGSOrgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial OfficerGlobeNewswireGERMANTOWN, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the
3y agoORGSOrgenesis Announces Name Change of Morgenesis Business Unit to OctomeraGlobeNewswireGERMANTOWN, Md., July 11, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the
3y agoORGSOrgenesis and University of California, Davis Sign Partnership Agreement for Rollout of Cell and Gene Therapy Mobile Processing Units and Labs Throughout CaliforniaGlobeNewswireGERMANTOWN, Md. and DAVIS, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies
3y agoORGSClaudia Zylberberg Appointed as Independent Board Member of POCare Business Subsidiary of OrgenesisGlobeNewswireGERMANTOWN, Md., May 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), today
3y agoORGSOrgenesis Academy Graduates First Class of Cell and Gene Therapy Experts from theraCell Laboratories-backed Master's ProgramGlobeNewswireGERMANTOWN, Md., May 22, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), today
3y agoORGSOrgenesis to Participate in Benchmark's 3rd Annual Healthcare House Call Virtual 1x1 Investor Conference on May 23, 2023GlobeNewswireGERMANTOWN, Md., May 19, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point
3y agoORGSOrgenesis Announces Collaboration Agreement with SCTbio to Expand POCare Sites in the Czech Republic and Enhance Capabilities for the Production of Lentivirus VectorsGlobeNewswireGERMANTOWN, Md. and PRAGUE, Czech Republic, May 18, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:ORGS) ("Orgenesis"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) through
3y agoORGSOrgenesis Provides Business Update for the First Quarter of 2023 and Reports Continued Progress on its POCare StrategyGlobeNewswireGERMANTOWN, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today
3y agoORGSOrgenesis Secures an Additional $5 Million Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Service SubsidiaryGlobeNewswireGERMANTOWN, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point
3y agoORGSOrgenesis CEO Vered Caplan Featured in Keynote Series at INTERPHEX Conference to Discuss Innovations in Cell & Gene Therapy ManufacturingGlobeNewswireGERMANTOWN, Md., April 25, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the
3y agoORGSOrgenesis Reports 98% Year-Over-Year Increase in Revenue to $13.6 Million for the Fourth Quarter of 2022GlobeNewswireRapid growth reflects progress of POCare Platform Orgenesis to host conference call today at 11:00 AM ET GERMANTOWN, Md., March 21, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the
3y agoORGSOrgenesis Schedules Fourth Quarter 2022 Business Update Conference CallGlobeNewswireGERMANTOWN, Md., March 17, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies, today announced
3y agoORGSOrgenesis Signs MOU with University of California, Davis to Develop a Collaboration Agreement to Deploy Cell and Gene Therapy Mobile Processing Units and Labs Across CaliforniaGlobeNewswireGERMANTOWN, Md., March 16, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the
3y agoORGSOrgenesis Inc. Announces Closing of $3.7 Million Registered Direct OfferingGlobeNewswireGERMANTOWN, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Orgenesis, Inc. (Nasdaq: ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies, today
3y agoORGSOrgenesis Inc. Announces Pricing of $3.7 Million Registered Direct OfferingGlobeNewswireGERMANTOWN, Md., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Orgenesis, Inc. (Nasdaq: ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies, today
3y agoORGSOrgenesis and Kurve Therapeutics Announce Pre-Clinical Study Results for a Cell-Based Oncolytic Virus Bearing Product Demonstrating Over 50% Reduction in a Murine Glioblastoma ModelGlobeNewswireGERMANTOWN, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies, and Kurve
4y agoORGSOrgenesis Achieves Revenue of $8.0 Million for the Third Quarter of 2022GlobeNewswireSecures up to $50 Million of Funding from Metalmark Capital Partners Expected to Accelerate Rollout of Point-of-Care Services Reduces operating expenses by 49% to achieve nearly breakeven income from operation for the
4y agoORGSOrgenesis Schedules Third Quarter 2022 Business Update Conference CallGlobeNewswireGERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies, today announced
4y agoORGSOrgenesis Secures up to $50 Million Subsidiary-Level Investment from Metalmark Capital to Accelerate Growth of Point-of-Care ServicesGlobeNewswireGERMANTOWN, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the
4y agoORGSOrgenesis Achieves Revenue of $7.2 Million for the Second Quarter of 2022GlobeNewswireSecures Funding from Metalmark Capital Partners to Drive Growth Orgenesis to Host Conference Call Today, August 16, 2022 at 11 AM Eastern Time GERMANTOWN, Md., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Co
4y agoORGSOrgenesis Schedules Second Quarter 2022 Business Update Conference CallGlobeNewswireGERMANTOWN, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference cal
4y agoORGSOrgenesis Achieves Revenue of $7.2 Million for the First Quarter of 2022GlobeNewswireGERMANTOWN, Md., May 24, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies, today provided a business update for first quarter
4y agoORGSOrgenesis Led Consortium Awarded €4M European Innovation Council Pathfinder GrantGlobeNewswireGERMANTOWN, Md., May 03, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies, today announces a consortium led by one of its subs
4y agoORGSOrgenesis Inc. Announces $14.8 Million Private PlacementGlobeNewswireGERMANTOWN, Md., March 31, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies, announced today that it has entered into a defini
4y agoORGSOrgenesis Reports Revenue Growth of 364% for 2021 and Provides Business UpdateGlobeNewswireGERMANTOWN, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies, today reports its financial results for the year
4y agoORGSOrgenesis Schedules 2021 Fiscal Year Business Update Conference CallGlobeNewswireGERMANTOWN, Md., March 29, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference